Deutsche Bank
PHAT icon

Deutsche Bank’s Phathom Pharmaceuticals PHAT Stock Holding History

Deutsche Bank’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$545K Buy
50,205
+13,746
+38% +$157K ﹤0.01% 2725
2026
Q1 		$405K Buy
36,459
+3,079
+9% +$38.9K ﹤0.01% 2685
2025
Q4 		$554K Buy
33,380
+3,808
+13% +$54.4K ﹤0.01% 2516
2025
Q3 		$348K Buy
29,572
+3,493
+13% +$36K ﹤0.01% 2745
2025
Q2 		$250K Sell
26,079
-1,093
-4% -$6.05K ﹤0.01% 2842
2025
Q1 		$170K Sell
27,172
-3,041
-10% -$18.5K ﹤0.01% 3025
2024
Q4 		$245K Buy
30,213
+9,986
+49% +$124K ﹤0.01% 3005
2024
Q3 		$366K Buy
20,227
+5,156
+34% +$72.1K ﹤0.01% 2631
2024
Q2 		$155K Buy
15,071
+809
+6% +$8.33K ﹤0.01% 2947
2024
Q1 		$151K Sell
14,262
-3,437
-19% -$29.2K ﹤0.01% 2975
2023
Q4 		$162K Buy
17,699
+4,870
+38% +$42K ﹤0.01% 2987
2023
Q3 		$133K Buy
12,829
+1,700
+15% +$23.3K ﹤0.01% 3024
2023
Q2 		$159K Sell
11,129
-5,070
-31% -$58.5K ﹤0.01% 3021
2023
Q1 		$116K Buy
16,199
+5,356
+49% +$47K ﹤0.01% 3263
2022
Q4 		$122K Buy
10,843
+152
+1% +$1.57K ﹤0.01% 3238
2022
Q3 		$118K Buy
10,691
+542
+5% +$5.16K ﹤0.01% 3234
2022
Q2 		$86K Sell
10,149
-1,392
-12% -$14.3K ﹤0.01% 3585
2022
Q1 		$157K Sell
11,541
-1,298
-10% -$21K ﹤0.01% 3388
2021
Q4 		$253K Buy
12,839
+642
+5% +$15.1K ﹤0.01% 3261
2021
Q3 		$392K Sell
12,197
-372
-3% -$12.4K ﹤0.01% 3191
2021
Q2 		$425K Buy
12,569
+5,144
+69% +$184K ﹤0.01% 3326
2021
Q1 		$279K Sell
7,425
-657
-8% -$27.5K ﹤0.01% 3454
2020
Q4 		$268K Buy
8,082
+2,071
+34% +$83.9K ﹤0.01% 3301
2020
Q3 		$220K Buy
6,011
+520
+9% +$18K ﹤0.01% 3164
2020
Q2 		$181K Buy
5,491
+1,781
+48% +$68.4K ﹤0.01% 3186
2020
Q1 		$96K Sell
3,710
-216
-6% -$7.22K ﹤0.01% 3271
2019
Q4 		$121K Buy
+3,926
New +$98.7K ﹤0.01% 3493

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Deutsche Bank's PHAT Position: Q2 2026 in Review

Deutsche Bank increased its Phathom Pharmaceuticals (PHAT) stake by 38% in Q2 2026, buying an estimated $157K and bringing the position to 50,205 shares worth $545K. The position accounts for ﹤0.01% of the portfolio, ranked #2725.

Deutsche Bank first reported a position in PHAT in Q4 2019 and has held it in 27 quarters since. The position peaked at $554K in Q4 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Deutsche Bank held 50,205 shares of Phathom Pharmaceuticals worth $545K as of Q2 2026.
  • Deutsche Bank bought 13,746 Phathom Pharmaceuticals shares in Q2 2026, an estimated $157K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #2725 holding.
  • Deutsche Bank first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Deutsche Bank's Phathom Pharmaceuticals position peaked at $554K in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.